These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 16864049)

  • 1. Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era.
    Grigg A; Hughes T
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):795-807. PubMed ID: 16864049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors?
    Maziarz RT
    Curr Opin Hematol; 2008 Mar; 15(2):127-33. PubMed ID: 18300759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing therapy of chronic myeloid leukemia.
    Deininger MW
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):144-54. PubMed ID: 17379100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment.
    Simon W; Segel GB; Lichtman MA
    Blood Cells Mol Dis; 2006; 37(2):116-24; discussion 125-7. PubMed ID: 16904348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
    Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
    Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of CML in pediatric patients: should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy?
    Pulsipher MA
    Pediatr Blood Cancer; 2004 Oct; 43(5):523-33. PubMed ID: 15382266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase.
    Atallah E; Cortes J
    Curr Opin Hematol; 2007 Mar; 14(2):138-44. PubMed ID: 17255791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
    Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
    Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic stem cell transplantation for chronic myeloid leukemia-status in 2007.
    Goldman J
    Bone Marrow Transplant; 2008 Aug; 42 Suppl 1():S11-S13. PubMed ID: 18724281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful interim therapy with imatinib prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute myeloid leukemia.
    Cho BS; Kim HJ; Lee S; Eom KS; Min WS; Lee JW; Kim CC
    Eur J Haematol; 2007 Aug; 79(2):170-3. PubMed ID: 17608710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [An advance in the treatment of CML].
    Ohnishi K
    Gan To Kagaku Ryoho; 2007 Dec; 34(13):2185-90. PubMed ID: 18079618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and emerging treatment options in chronic myeloid leukemia.
    Jabbour E; Cortes JE; Giles FJ; O'Brien S; Kantarjian HM
    Cancer; 2007 Jun; 109(11):2171-81. PubMed ID: 17431887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to imatinib mesylate in chronic myeloid leukaemia.
    Melo JV; Chuah C
    Cancer Lett; 2007 May; 249(2):121-32. PubMed ID: 16949736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation.
    Anderlini P; Sheth S; Hicks K; Ippoliti C; Giralt S; Champlin RE
    Biol Blood Marrow Transplant; 2004 Dec; 10(12):883-4. PubMed ID: 15570257
    [No Abstract]   [Full Text] [Related]  

  • 15. Chronic myeloid leukemia: a historical perspective.
    Goldman JM
    Semin Hematol; 2010 Oct; 47(4):302-11. PubMed ID: 20875546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
    Tanaka R; Kimura S
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Stem cell transplantation in the imatinib era].
    Masszi T
    Orv Hetil; 2005 May; 146(18 Suppl 1):900-4. PubMed ID: 15921302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced-intensity conditioning for allogeneic stem cell transplantation in patients with chronic myeloid leukemia is associated with better overall survival but inferior disease-free survival when compared with myeloablative conditioning - a retrospective study of the Czech National Hematopoietic Stem Cell Transplantation Registry.
    Faber E; Koza V; Vitek A; Mayer J; Sedlacek P; Zak P; Zapletalova J; Benesova K; Krejcova H; Steinerova K; Maresova I; Cetkovsky P;
    Neoplasma; 2007; 54(5):443-6. PubMed ID: 17688375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia.
    Perz JB; Khorashad JS; Marin D; Apperley JF; Olavarria E
    Haematologica; 2006 Aug; 91(8):1145-6. PubMed ID: 16870551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis.
    Palandri F; Amabile M; Rosti G; Bandini G; Benedetti F; Usala E; Angelucci E; Tiribelli M; Fanin R; Martinelli G; Baccarani M
    Bone Marrow Transplant; 2007 Feb; 39(3):189-91. PubMed ID: 17211436
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.